Scientific Publications

A Prostate-Specific Antigen–Activated Channel-Forming Toxin as Therapy for Prostatic Disease
Article - JNCI, Vol.99, Issue 5 pp, 376-385

A Prostate-Specific Antigen (PSA) activated channel-forming toxin as therapy for prostatic disease
Poster - EORTC-NCI-AACR Symposium, November 2006, Prague, Czech Republic.

PSA-Activated Proaerolysin as a Prostate Specific Cancer Therapy
Abstract/Poster - AACR, April 2006, Washington DC, USA.

Tumouricidal effects of a PSA-activated pore-forming toxin
Abstract - AACR, April 2005, Anaheim, USA.

Kioi, M., et al., Expression and targeting of interleukin-4 receptor for primary and advanced ovarian cancer therapy.
Cancer Res, 2005. 65(18): p. 8388.

Kay, N.E., et al., A recombinant IL-4-Pseudomonas exotoxin inhibits protein synthesis and overcomes apoptosis resistance in human CLL B cells.
Leuk Res, 2005. 29(9): p. 1009.

Garland, L., et al., Phase I trial of intravenous IL-4 pseudomonas exotoxin protein (NBI-3001) in patients with advanced solid tumors that express the IL-4 receptor.
J Immunother, 2005. 28(4): p. 376.

Weber, F., et al., Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma.
J Neurooncol, 2003. 64(1-2): p. 125.

Kawakami, K., et al., Targeting interleukin-4 receptors for effective pancreatic cancer therapy.
Cancer Res, 2002. 62(13): p. 3575.

Husain, S.R., et al., Interleukin-4 receptor-directed cytotoxin therapy of AIDS-associated Kaposi's sarcoma tumors in xenograft model.
Nat Med, 1999. 5(7): p. 817.